Holm-Jorgensen Rasmus
Known title: Chief Financial OfficerCIK: 0001950496
Associated companies
Transaction History
| ACRV | ▼ Sell | Tax Withholding | 434 | $2K | 2/14/2025 | View on chart |
| ACRV | ▼ Sell | Tax Withholding | 368 | $3K | 11/14/2024 | View on chart |
| ACRV | ▼ Sell | Tax Withholding | 368 | $3K | 8/14/2024 | View on chart |
| ACRV | ▼ Sell | Tax Withholding | 368 | $3K | 5/14/2024 | View on chart |
| ACRV | ▼ Sell | Tax Withholding | 434 | $1K | 2/14/2024 | View on chart |
| ACRV | ▼ Sell | Tax Withholding | 1,470 | $7K | 11/14/2023 | View on chart |
| ACRV | ▲ Buy | Option Exercise | 9,500 | $34K | 6/16/2023 | View on chart |
| ACRV | ▲ Buy | Grant | 20,030 | $0 | 11/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Acrivon Therapeutics noted among health‑care stocks moving in after‑market
Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.
Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.